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Abstract 
Traditional treatment regimens for adult acute lymphoblastic leukemia, including allogeneic 
hematopoietic cell transplantation, result in an overall survival of about 40%, a figure 
hardly comparable with the extraordinary 80-90% cure rate currently reported in children. 
When translated to the adult setting, modern pediatric-type regimens improve the survival 
to about 60% in young adults. The addition of tyrosine kinase inhibitors for patients with 
Philadelphia chromosome positive disease and the measurement of minimal residual 
disease to guide risk stratification and post-remission approaches has led to further 
improvements in outcomes. Relapsed disease and treatment toxicity - sparing no patient 
but representing a major concern especially in the elderly - are the most critical current 
issues awaiting further therapeutic advancement. Recently, there has been considerable 
progress in understanding the disease biology, specifically the Philadelphia-like signature 
as well as other high-risk subgroups. In addition, there are several new agents that will 
undoubtedly contribute to further improvement in the current outcomes. The most 
promising agents are new the monoclonal antibodies, immunomodulators, and chimeric 
antigen receptor T cells and, to a lesser extent, several new drugs targeting key molecular 
pathways involved in leukemic cell growth and proliferation. This review examines the 
evidence supporting the increasing role of the new therapeutic tools and treatment options 
in different disease subgroups, including frontline and relapsed/refractory disease. It is 
now possible to define the best individual approach based on to the emerging concepts of 
precision medicine. 
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Introduction 
In Western countries, new cases of adult acute lymphoblastic leukemia (ALL) occur at an 
annual rate of approximately 1/100,000, with a bimodal distribution decreasing at 45-54 
years and increasing again above 55 years, totaling in the United States about 2300 new 
cases/year for patients above 15 years of age (1750 between 15-55 years).1,2 Over the 
past decade, we have witnessed an incredible therapeutic improvement. Currently, 
pediatric patients have an estimated 5-year overall survival (OS) approaching 90%.3-5 
Modern pediatric programs thrive on an intensified use of corticosteroids (mainly 
dexamethasone), antimetabolites (especially methotrexate and 6-mercaptopurine) and L-
asparaginase/pegylated-asparaginase, and rely on minimal residual disease (MRD) 
analysis for further dose intensification or allogeneic hematopietic cell transplantation 
(HCT).6-8  
Recent advances using pediatric regimens in adults 
The results in adult ALL have unfortunately not kept pace, with OS rates below 45%9 
despite the addition of central nervous system (CNS) prophylaxis, ‘late’ intensification with 
prolonged maintenance chemotherapy and an extensive use of HCT in high risk (HR) 
subsets. Currently, pediatric inspired regimens are being administered in young adult 
patients, leading to improvements in EFS (event-free survival) and OS rates as compared 
to historical controls.10-13 This approach, initially reserved for adolescents and young adults 
(AYA, less than 40 year-old),10,14,15 and later applied to patients up to 50-60 years of age, 
11,12,16 has increased 5-year OS rate to ≥ 50%, and up to 70-80% in favorable subsets 
(AYA, SR [standard risk]), MRD negative) (supplemental Table 1),17 but not in older 
patients, whose survival decreases progressively to less than 20%.2-4 Finally, allogeneic 
HCT is often considered in first complete remission (CR) in adults with HR disease in order 
to reduce the risk of relapse,18 but potential benefits may be offset by transplant-related 
morbidity and mortality, especially in the elderly.19 
Risk stratification 
Current risk stratification criteria reflect the clinical and prognostic heterogeneity of ALL 
and determine which patients should undergo more intensive treatment including HCT, 
due to the high risk of relapse. Besides patient-related characteristics, namely advanced 
age and poor performance status, recognized risk factors include hyperleucocytosis, early 
T-precursor (ETP) phenotype and adverse cytogenetics/genetics, i.e. t(9;22)/BCR-ABL1 
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rearrangement (Philadelphia chromosome positive [Ph+] ALL), Ph-like ALL, 
t(4;11)/KMT2A-AFF1 rearrangement, hipodiploidy, mutated TP53 and other 
abnormalities.20 In all studies, MRD has proven to be a major independent risk factor for 
relapse.21 In contrast to MRD-negative patients (typically defined as ˂ 10-4), MRD-positive 
patients are seldom cured with chemotherapy alone. In prospective trials performed over 
the past 25 years, enrolling more than 1500 patients,22-24 OS was between 60-80% with 
chemotherapy alone in MRD-negative patients, even in HR subsets and Ph+ ALL.25 
Instead MRD-positive patients benefit partially from HCT, however with OS rates of 50% or 
less in intention-to-treat analyses, due to the cumulative effects of pre-and post-
transplantation relapse and tranplant-related deaths.26-28 
Current therapeutic limitations 
The treatment of older patients represents a major obstacle,29 and, at all ages, relapse 
affects one third or more of the patients and remains an unsolved issue due to extremely 
poor results with standard salvage chemotherapy. An international study on 1706 patients 
with refractory or recurrent (R/R) B-cell precursor (BCP) ALL reported 3-year survival rates 
of only 10%.30 Results are worse in Ph+ ALL31 and T-cell precursor (TCP) ALL, with some 
mitigation provided by nelarabine.32 Another concern is high-grade toxicity causing deaths 
in remission, which increases with age and with transplants (20% or more in most studies). 
The challenge of new management options 
Despite these constraints, the management of adult ALL can improve further. This new era 
started with the advent of tyrosine kinase inhibitors (TKI) for Ph+ ALL,33 flourished with 
immunotherapy for BCP ALL and is now empowered by novel immunotherapeutics 
(Tables 1 and 2)13,34-64 and several small molecules targeting critical metabolic pathways 
(Figure 1, Table 3), used alone or in combination in specific ALL subsets (Figure 2). While 
more robust data on toxicity, dosing and therapeutic implications are required, and will be 
generated by ongoing trials (Clinical.Trials.gov repository, accessed April 2017; 
supplemental Tables 2-7), some of these agents could improve the cure rate and prompt a 
shift in the therapeutic regimens for ALL. The most promising agents currently available 
are those targeting cell membrane antigens (CD19, CD20, CD22) and major molecular 
pathways controlling cell proliferation and apoptotic response (multiple kinases and 
members of Bcl-2, TP53, RAS, mTOR/PI3K, pre-B/B-cell receptor and NOTCH networks). 
Furthermore, new molecular and drug profiling techniques  might become essential to 
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define targets and compounds deserving evaluation in trials or individual patients. At 
present, this new strategy is still largely speculative, especially in frontline therapy, since 
both molecular sequencing and new drug sensitivity screening models have not yet been 
sufficiently tested or validated in early clinical trials.This review will focus on the rationale 
supporting this change and will illustrate how new treatment approaches and related 
experimental work are likely to modify and improve the management of adult ALL. 
Actionable target and drug screening 
Molecular profiling                                                                                                                
While targets for immunotherapy can be identified by diagnostic immunophenotype, ALL  
subtype classification and target identification relies mostly on molecular genetics for the 
detection of gene rearrangements, translocations and actionable recurrent mutations with 
genome-wide technologies.65-69 In the era of precision medicine, molecular profiling has 
gained in importance for the management of this disease. New concepts for targeted 
therapies and combinatory approaches with immunotherapy and/or chemotherapy require 
sophisticated experimental modeling and are now increasingly entering into clinical 
development (Figure 2 and supplemental Tables 2-9).  
Drug profiling platforms                                                                                                              
Since the molecular classification of ALL is often insufficient to capture the complex 
biology of the disease and provide a predictive guide for treatment,70 functional screening 
approaches are being explored to generate drug response profiles directly from clinical 
samples, leading to proof of concept results and raising interest to explore  this approach 
in clinical trials (Figure 3). The first screening platform tested a customized library of 
kinase inhibitors,71 leading to a prospective trial in relapsed acute myeloid leukemia (AML). 
The Primary Blood Cancer Encyclopedia project, which integrates short-term drug testing 
data with transcriptome and DNA methylome analysis, strongly supported the value of 
phenotypic screening in hemato-oncology.72 Some platforms are based on large viability 
assays for high-throughput testing72-74 with the advantage of simplicity and lower costs, 
and others more sophisticated are based on automated microscopy which can 
discriminate leukemia cells with the normal microenvironment at the single cell level.75,76 
Functional screens of ALL samples maintained on mesenchymal stromal cells identified 
unexpected dependencies in defined HR ALL subtypes77, captured response 
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heterogeneity across ALL subtypes, discriminated patients based on drug sensivitiy 
efficiently75,78,79 and detected new pathways and vulnerabilities in resistant disease.75,77-80  
New disease models                                                                                                        
Drug development can be accelerated using humanized mouse models with primary 
leukemia81,82 that enable systematic preclinical drug testing.83,84 Patient-derived xenograft 
(PDX) biobanks integrate extensive genomic and clinical information,75,85-88 mirror the 
clonal architecture of leukemia initiating cells,89-92 maintain the genetic composition of the 
xenografted sample,75,77,89,93 and enable testing of new agents on samples from clinically 
representative cohorts of patients, providing survival cues and a longer window for 
combinatorial drug testing. Impressive results have been reported from a first trial 
assessing drug sensitivity in patients with refractory hematologic malignancies using multi-
parametric image-based immunocytometry to distinguish the effect of drugs on malignant 
and normal blood cells.76 Out of 48 patients, informative results could be used for 17 
patients receiving assay-guided treatment, including 2 BCP ALL patients, resulting in 
responses in 8 patients (1 with ALL). These results will stimulate the design of larger 
clinical studies on specific disease entities, in order to capture the full potential of drug 
response profiling with the aim to avoid unnecessary toxicity of inappropriate salvage 
regimens and improve responses in selected subgroups.  
Functional drug screening for molecularly unclustered ALL                                                     
The usefulness of functional drug screening is being explored in patients with ALL not 
included in specific molecular clusters. For example BCL2-dependent ALL was identified 
by screening PDX models for sensitivity to BH3 mimetics including venetoclax75,77,85,94,95 
and drug combinations established to overcome resistance.75,96 Similarly, selective 
sensitivity to alternative RIP-1 dependent cell death pathways (necroptosis by SMAC 
mimetics) not exploited by current anti-leukemic agents were discovered.80,97 PDX models 
have also been used to understand elucidate the critical dependence on altered metabolic 
function.98-100 This underscores the importance to cross-reference drug responses over 
many samples in a structured database to establish the effective and expected dose-
response range for relevant outliers, that is a drug sensitivity pattern not predicted by the 
molecular ALL subset. 
New management options with immunotherapeutics                                                                                                                                                                           
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Rituximab                                                                                                                                         
In BCP ALL, the expression of CD20 confers a poor prognosis.101 Rituximab, a chimeric 
anti-CD20 antibody, was evaluated in combination with chemotherapy for untreated 
patients with Ph- CD20+ BCP ALL. At the MD Anderson Cancer Center (MDACC), 
rituximab was added to the first four courses of the hyper-CVAD regimen.44 The results 
demonstrated an improved CR duration, a lower relapse rate and an improved OS, but 
only in patients younger than 60 years as compared to historical controls (70% vs. 38%, P 
< .001; and 75% vs. 47%, P = .003). Comparable data were produced by the German 
adult ALL Study Group.45 The French-Belgian-Swiss Group for Research on Adult ALL 
(GRAALL) evaluated the addition of rituximab in a phase III study using a pediatric inspired 
regimen:13  patients 18-59 years old received 16-18 rituximab doses, resulting in improved 
the 2-year EFS from 52% to 65% (P = .004), due to a decreased relapse rate with no 
increase in toxicity.                                                                                                                                                         
Blinatumomab                                                                                                                          
New antibody constructs have shown promise for R/R ALL.102 Blinatumomab, a bispecific 
T-cell engager (BiTE®) construct, received US Food and Drug Administration and 
European Medicines Agency approval. Blinatumomab simultaneously targets CD19 
(present on most BCP ALL cells) and CD3 (present on cytotoxic T-cells) and acts to bring 
ALL cells into proximity of T-cells, capable of tumor eradication. In a phase II study,38 189 
adult patients with Ph- R/R BCP ALL received blinatumomab with 43% (81/189) of them 
achieving CR or CR with defective hematologic recovery (CRh), and 40% of responders 
able to successful transition to allogeneic HCT Importantly, 60 out of 73 evaluable CR 
patients (82%) achieved MRD negativity. Results were similar in the phase III trial with a 
44% CR/CRh rate in the blinatumomab arm compared to 25% in patients receiving 
chemotherapy,39 and 76% compared to 48% turning MRD negative. Although generally 
well tolerated, grade 3 or higher cytokine release syndrome (CRS) and neurologic toxicity 
was seen in 4.9% and 9.4% of patients, respectively. Blinatumomab was tested as a single 
agent in patients with R/R Ph+ ALL, where it induced a CR rate of 36% associated with 
88% MRD-negative status,40 and in Ph- MRD-positive ALL, achieving an excellent 
response rate of 78%, with prolonged survival, occasionally without HCT.36,103 Resistance 
mechanisms include a defective T-memory/regulator cell response, PD1/PD-L1 
overexpression104 and emergence of CD19-negative subclones.105                                                                                          
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Inotuzumab ozogamicin (INO)                                                                                                                             
INO is an anti-CD22 antibody conjugated to calicheamicin in late clinical development. A 
phase I/II study demonstrated a CR/CRi (incomplete hematologic recovery) rate of 68% 
with 84% of responding patients achieving MRD-negativity.53 In a recent phase III trial INO 
was superior to salvage chemotherapy for R/R ALL. Among the first 218 patients 
randomized, 81% of those assigned to INO achieved CR compared to 29% who received 
standard-of-care, with higher percentage of MRD-negative cases (78% versus 28%, P < 
.0001).54 Duration of remission and OS favored INO, as confirmed by a long-term update 
reporting a 2-year rate of 22.8% vs 10% in standard care group (P .0001).106 However, 
hepatotoxicity was more frequent in the INO group (51% versus 34%), including incidence 
of sinusoidal obstruction syndrome (SOS) (13% versus < 1%). Although most of the cases 
occurred after HCT, 5 patients (3%) developed SOS with INO therapy alone.107            
Given the proven efficacy of this compound on these studies, INO is being combined with 
chemotherapy in the frontline setting. Using a mini-hyper-CVD regimen 
(cyclophosphamide, vincristine, dexamethasone) with INO in elderly, 47 out of 48 
evaluable patients (98%) achieved a CR/CRi (35 CR), coupled with flow-cytometric MRD-
negative status in 76%. Two-year PFS and OS were 52% and 66%, respectively.56,108 
Chimeric antigen receptor (CAR) T-cells                                                                                                                             
Cellular immunotherapy with CD19-directed CAR T-cells represents another promising 
approach for R/R disease. Anti-CD19 CAR T-cells have been the most extensively studied 
in trials using “second-generation” receptors, which comprise three components: an 
extracellular antigen-recognition domain derived from the single-chain variable fragment of 
a monoclonal antibody (scFv), an intracellular signaling domain (the CD3z chain from the 
T-cell receptor), and a co-stimulatory domain (most commonly, 4-1BB or CD28).109-111 
Initial phase I/II studies using the CTL019 construct reported a 90% CR rate in 30 patients 
(25 pediatric, 5 adult).110 In addition, 88% of the patients who achieved a CR were MRD-
negative. Responses were durable with 7 relapses and 19 ongoing remissions (2 to 24 
months), with 15 patients receiving no further therapy. High rates of CAR T-cell 
persistence (68%) and associated B-cell aplasia was reported at 6 months. In 
collaboration with Novartis, CTL019 was administered to 75 children and young adults, 
with 81% achieving CR and concurrent MRD-negative status. At a median follow-up of 
10.6 months, 29 remained in CR. One-year EFS and OS were 50% and 76%, 
respectively.60 This led to the approval of tisagenlecleucel (KymriahTM), the first CAR 
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product in the US. The outcomes in adult patients treated with CAR T-cells has been less 
impressive with median EFS and OS of 6.1 months and 12.9 months, respectively.63                                                                                                                                           
CAR T-cells but not NK cells112 could also be effective against CNS leukemia.113 Although 
anti-CD19 CAR T-cells can generate rapid and impressive responses, therapy is 
associated with a unique set of severe side effects. The two major toxicities include CRS 
and neurotoxicity. In the CTL019 study, all patients experienced signs and symptoms of 
CRS with 8 of 30 patients requiring transfer to intensive care unit.110 Fortunately, 
tocilizumab, an anti-IL6 receptor antibody, was found effective and has become the 
mainstay of management for severe CRS, as it is well-tolerated and rapidly effective in the 
majority of cases. Current approaches include optimization of the CAR T-cell product in 
defined proportions of CD4 and CD8 T-cell subsets, development of humanized CARs, 
CARs with two co-stimulatory domains, allogeneic CARs and CARs against other antigens 
such as CD22.  
New management options in molecularly-defined ALL subsets                                                                            
Ph+ ALL                                                                                                                                
Outcome of Ph+ ALL was dramatically improved by TKIs.114-118 Single-agent imatinib or 
dasatinib plus corticosteroids therapy, pioneered by the Gruppo Italiano Malattie 
Ematologiche dell’Adulto (GIMEMA)114,119 induced CR virtually in all patients without risk of 
induction death. With TKI-chemotherapy combinations, CR rate exceeded 95% but death 
occurred in 2-7% of the cases. In a randomized trial from GRAALL,116 a combination of de-
escalated chemotherapy plus TKI resulted in less induction toxicity and non-inferior CR 
and survival results compared to standard chemotherapy plus TKI. In a MDACC study, 
ponatinib combined with Hyper-CVAD led to an excellent 83% 2-year OS, even without 
HCT115. In elderly and/or frail patients (median age 68 years, range 27-85 years), ponatinib 
monotherapy (GIMEMA) resulted in 87.5% 1-year OS, associated with a 45% molecular 
response rate.120 Postremission consolidation is still based on intensive chemotherapy 
(plus TKI) and HCT, when feasible. This “global” strategy led to survival rates approaching 
50%, thus meaning we still need to improve. Chemotherapy-free trials with TKI-
immunotherapy combinations (e.g. TKI-blinatumomab) are ongoing (NCT02744768) and 
will clarify the place of this antibody construct especially in eradicating MRD. As for other 
ALL subsets, MRD persistence is associated with recurrence while its negativity may 
identify patients with favorable prognosis in whom the indication for HCT could be 
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reconsidered to spare morbidity and mortality.25                                                                                           
With these premises, relapse remains relatively frequent event and is often sustained by 
mutations, the most deleterious being T315I. New potentially active agents include 
axitinib,73 a vascular endothelial growth factor receptor inhibitor active in T315I mutant, a 
new TKI, danusertib,121 and ABL001 (asciminib),122 a novel allosteric TKI that binds to the 
myristoyl pocket of ABL1, causing an inactive kinase conformation (NCT02081378 phase I 
trial for patients intolerant/refractory to standard TKI). Notably, a drug sensitivity testing 
platform123 allowed the identification of axitinib as a selective inhibitor of the T315I 
mutant.73 As for combinatory studies, of interest is the simultaneous administration of 
dasatinib, ruxolitinib and dexamethasone, which in vitro was shown to restore cytokine 
dependency, inhibit STAT3 and STAT5 activation and prevent leukemia initiating cell 
growth and acquisition of mutations (NCT02494882),124 and the combination of ruxolitinib 
with nilotinib (NCT01914484). In cases with IKZF1 impairment, retinoids can induce IKZF1 
re-expression, stimulate cell maturation and restore in vitro TKI sensitivity.125 Moreover, 
promoters of myelomonocytic differentiation can successfully induce Ph+ ALL cells into 
non-leukemic monocytes/macrophages.126 
Ph-like ALL                                                                                                                            
The Ph-like subgroup, initially identified by means of gene expression profiling, accounts 
for about 20% of adult BCP ALL cases,with a prevalence in AYA. These cases are 
characterized by a transcriptional profile similar to that of Ph+ ALL but lacking the 
t(9;22)/BCR-ABL1 rearrangement.127-130 Instead, the underlying genomic lesions are 
heterogeneous making its recognition difficult and uneven among trials. CRLF2 
rearrangements are detected in about 50%, lesions affecting ABL class genes (i.e. ABL1, 
ABL2, CSF1R, PDGFRA, PDGFRB) in roughly 10%, JAK/STAT genes (i.e. JAK1-3, IL7R, 
and CRLF2 mutations) in <10%. Rearrangements in other TKs and EPOR gene are 
extremely rare. IKZF1 deletions occur in up to 80% of the cases. Patients with Ph-like ALL 
have a poorer outcome when compared to other BCP ALL subsets and is not yet clear 
whether they should receive a HCT upfront based on MRD persistence only.128,131 Given 
the activated kinome profile several groups are currently testing the combination of TKIs 
with chemotherapy. Children’s Oncology Group (COG) is testing ruxolitinib in CRLF2-
rearranged and/or JAK-STAT deregulated patients (NCT02723994) or dasatinib in 
untreated patients (NCT02883049), while MDACC is testing these drugs in pre-treated 
patients (NCT02420717), with disappointing results.132 Other experimental approaches 
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employ a variety of inhibitors based on the individual molecular profile. The pan-TKI 
ponatinib could be effective regardless of the underlying genetic lesion.133                                      
MLL-rearranged ALL 
The prognosis of t(4;11)/KMT2A-AFF1+ and other MLL-rearranged ALLs is poor and could 
be improved by new targeted approaches. MLL (i.e. KMT2A) rearrangements are 
associated with high levels of H3K79 methylation catalyzed by the DOTL1 enzyme. 
Therefore DOT1L inhibitors, particularly EPZ-5676 (pinometostat) have been tested in R/R 
cases (NCT02141828, NCT01684150) in both pediatric and adult cohorts.134 Furthermore, 
MLL-rearranged cases express high levels of Bcl-2, BAX, and BIM but relatively low levels 
of BCL-XL and MCL-1, a mechanism is directly sustained by KMT2A rearrangement on 
BCL2 expression and is partly mediated by interaction with H3K79me2/3. As a 
consequence, in vitro and xenograft model studies showed that the Bcl-2 inhibitor 
venetoclax induces cell killing in synergy with chemotherapy.85,135,136 Additionally, histone 
deacetylase inhibitors (HDACi) can exert synergistic activity with cytarabine by repressing 
cytidine deaminase.137   
TCF3-rearranged ALL                                                                                                                                   
TCF3-PBX1+ ALL associated with t(1;19) represents about half the cases of the newly 
recognized pre-BCR (B-cell receptor)+ subset and is characterized by a favorable outcome 
with intensive treatment. These cases could be targeted by dasatinib since they 
overexpress a large number of TKs138 including the BCR-dependent TK ROR1139 and Mer 
TK which correlates with risk of CNS progression140, by idealisib due to the high levels of 
PIK3CD 141 and ibrutinib via downmodulation of the pre-BCR signaling on BCL6.98,142-143                                         
Instead, TCF3-HLF+ ALL is a very high risk subset associated with t(17;19), often with 
high levels of BCL2 expression recalling venetoclax as a potential therapeutic 
compound.77 Drug response profiling predicted robustly resistance to conventional drugs 
and confirmed a unique sensitivity to venetoclax. Combination therapy with 
dexamethasone, vincristine and venetoclax in PDX from two patients maintained CR for up 
to one year.77 
Hypodiploid BCP ALL                                                                                                   
Hypodiploid ALL is a rare poor prognostic subtype including near haploid (24–31 
chromosomes), low hypodiploid (32–39 chromosomes) and high hypodiploid (40–43 
chromosomes) ALL.144 RAS and PI3K pathways are frequently altered in near haploid 
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ALL, while TP53 and IKZF members are often mutated in low hypodiploid ALL, pinpointing 
to functional targeting using PI3K and PI3K/mTOR inhibitors.144,145 Germline mutational 
screening of TP53 should always be performed in these cases.                                                                                                                                  
Other BCP ALL subsets                                                                                                          
Many other actionable deletions or mutations are emerging in BCP ALL (and sometimes 
TCP ALL).127,144,146-148 These involve pathways affecting lymphoid development, cell cycle, 
regulation of transcription, lymphoid and RAS signaling, epigenetic modifications, cytokine 
receptors, TK expression and the JAK/STAT phosphorylation system  (Table 3). Focus is 
now on downstream members of the RAS pathway, namely with the MEK and PI3K 
inhibitor BEZ235 (NCT01756118), the allosteric MEK1/2 inhibitor selutetinib, trametinib 
and steroids, and FLT3 inhibitors, i.e. lestaurtinib, midostaurin and quizartinib – all being 
evaluated in phase I-II and III trials, respectively (NCT 00866281, NCT00557193 and 
NCT01411267). Among epigenetic regulators, HDACi vorinostat and panobinostat are 
being investigated in phase I-II trials for R/R disease (NCT01483690, NCT01321346 and 
NCT01321346), however with reports of toxicity. JAK2 inhibitors (ruxotilinb) and BCL2 
inhibitors might be used in cases harboring target mutations. SMAC mimetics, directly 
acting on apoptosis/necroptosis pathways, proteasome inhibitors and checkpoint 
inhibitors, have shown in vitro activity and are being studied (Supplemental files). The role 
of inhibitors of molecules involved in interaction with the marrow niche (NOTCH3 and 
NOTCH4) is still largely undetermined,149 while targeting SCD and SPP1 gene/proteins150 
and vascular endothelial growth factor A (with bevacizumab) could be useful against CNS 
leukemia.151 
B-ALL (mature B/Burkitt leukemia)                                                                                           
MYC rearrangements are the hallmark of B-ALL, leading to escape from cell cycle control 
and high proliferative rate. Thus inhibition of MYC-related pathways is an attractive option 
for refractory disease. MYC inhibitors JQ1 and THZ1 target MYC/MAX heterodimerization 
and CDK7 (THZ1), while dependency of MYC activation on multiple enhancers and ‘super-
enhancers’, such as a BET proteins and PI3K are targeted by mTOR or HDACi, Aurora 
kinase A and B and other BET inhibitors (I-BET 151, GSK525762, CPI-0610).152  New 
phase I trials are underway. 
TCP ALL                                                                                                                                    
TCP ALL accounts for about 25% of ALL cases and is further classified according to 
13 
 
maturation stage (early-, cortical- and mature-T). With modern pediatric-based regimens 
adopting MRD/risk-oriented intensification, outcome of TCP ALL may be excellent and 
superior to that of BCP ALL.  Among actionable molecular lesions,153 the most frequent is 
NOTCH1 mutation. NOTCH1 and the strictly associated gamma-secretase inhibitors (GSI) 
were tested in late stage disease, with some responses of short duration and considerable 
gut toxicity.154 The best study reported one CR and an overall 32% response rate in 25 
relapsed patients.155 Theoretically, targeting NOTCH1-related overexpression of 
chemokine receptor CCR7 and its ligand CCL19 could reduce the risk of CNS disease.156 
Many other targeting agents are being investigated, often in combination, like GSI and 
AKT inhibitors to revert glucocorticoid resistance157-159 (Figure 2, Table 3). Moreover, 
induction of T-cell receptor signaling led to apoptosis mimicking thymic negative 
selection,160 while targeting contact structures with the marrow microenvironment (CXCR4, 
CXCL12) reduces proliferation and the propagation potential of leukemic stem cells.161,162 
Notably PDX and drug screening models identified a subset of refractory T-ALL responsive 
to dasatinib in a nanomolar range, correlating with strong responses in vivo after 
resistance to multiple other treatments.75  
Early thymic precursor (ETP) ALL                                                                                                                                           
This peculiar diagnostic subset (weak/absent CD5 expression and early T/myeloid 
phenotype/genotype) is associated with poor outcome unless treated with very intensive 
MRD-based chemotherapy or HCT in first CR.163 ETP ALL is characterized by 
abnormalities typically observed in myeloid disorders including mutations in RUNX1, 
ETV6, GATA3, IDH1, IDH2, DNMT3A164,165 and the JAK/STAT pathway. In an 
experimental PDX model ETP ALL was exquisitely sensitive to ruxolitinib, which abrogated 
IL7-induced STAT5 phosphorylation.166 Furthermore, FLT3 inhibitors might be considered 
since mutations are detected in about 35% of cases.167                                                                 
Future directions 
We are entering an intensive phase of clinical investigations with new agents. To take 
advantage of these new treatment options we will have to gradually shift from R/R ALL to 
the frontline setting, where treatment resistance is less likely to occur.168 We will certainly 
need to develop solutions to integrate functional and genomic data for reference 
bioinformatics tools supporting clinical decisions, in accordance with studies in cancer 
patients including AML and childhood ALL169-171 For the exploration of individualized or 
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subset-specific treatment forms it will be crucial to design prospective clinical studies with 
modular elements to evaluate optimal strategies for chemotherapy,172 immunotherapy and 
combinations of molecularly targeted drugs and synergistic drug pairs,74,173 and detect 
activity in the early clinical trials more rapidly to pilot subsequent therapeutic 
developments. 
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Legends to the figures 
Figure 1. Actionable targets and drugs for innovative therapeutics in adult ALL.  
New therapeutic targets are membrane markers associated with B- or T-cell functions 
(type A), intracellular molecules involved in the regulation of key cell proliferation and 
differentiation pathways (type B) and receptors involved in the interaction with the 
supportive marrow niche (type C). Examples are shown for each category. Multi-targeted 
therapy is possible and synergy with chemotherapy is reported. Molecular profiling and ew 
drug profiling techniques can help identify suitable targets and the more active compounds 
and drug combinations, to be exploited in clinical trials of subset- and patient-specific 
therapy.  
 
Figure 2. Subset-specific approaches with new therapeutics in adult ALL. 
Clinical and pre-clinical experimental approaches with new management options for adult 
ALL and subsets (detailed sourcing and referencing in text and supplemental tables). 
Clinical trial evidence extracted from ClinicalTrials.gov repository, accessed April, 2017. 
 
Figure 3. Drug Response Profiling (DRP) of primary patient samples.  
(A) Workflow for phenotypical screens of co-cultures of primary ALL cells on human 
mesenchymal stromal cells using large scale automated microscopy. Generation of 
patient-derived xenografts (PDX) provide a renewable source of representative ALL cells 
for mechanistic research but may also be invaluable for deeper co-clinical validation 
experiments depending on the clinical situation. (B) Example of DRP output. IC50 values 
that were obtained based on dose-response curves with 8 datapoints after 72 h exposure 
of ALL cells to a selection of drugs are shown as a heatmap (red responses in the nM 
range, deep blue; resistance in the 10 μM range). Two examples of individual strong 
activity to the SMAC mimetic birinapant and to dasatinib are provided, with validation in an 
extended set of ALL PDX. MRD: minimal residual disease.  
